However, the company's name is still being withheld as well as the target therapy in order to protect their commercial interests. Unilife has made it known that the target therapy is approved in both the US and Europe for a common retina disease. This arrangement is going to support the lifecycle management of this approved therapy, which is administered via intravitreal injection into the eye. Unilife anticipates the commercial availability of Depot-ject with this therapy after a 12 to 24 month process of customization and regulatory approval for the drug-device combination.
This Depot-ject technology was designed to help administer the drug depot precisely into the eye - all while a clinician is in complete control over the implantation site (the implant is contained within the needle).
Mr. Alan Shortall, Chairman and Chief Executive Officer of Unilife said: "Unilife has created a broad portfolio of ocular delivery systems to enhance the intravitreal injection of ophthalmic therapies. The safety, simplicity and convenience of our Depot-ject delivery system has significant potential to improve patient care in the delivery of sustained release drug depots, and allow customers to further differentiate their brands of therapy from current or future competition. We are pleased to have signed our first commercial supply agreement within this fast-growing market segment, and look forward to supporting the customer in the rapid conversion of its approved therapy into our Depot-ject delivery system."
View the complete Press Release here.
Want to hear from Unilife directly? Join them at Drug Delivery Partnerships this January 28-30 in Boca Raton, FL. At the conference, Michael C. Ratigan, SVP & Chief Commercial Officer at Unilife will be presenting a Case Study titled "New Business Models for Partnering on Injectable Drug Delivery System".
Through multiple successful Partnerships, Unilife has created a new paradigm for injectable drug delivery that is pharmaceutical customer-centric, patient-centric, health care provider specific and outcomes focused; rather than the traditional industry model, which is rapidly becoming obsolete. Their dynamic business structure allows them to operate and serve partners with speed, agility, and reliability.
So be sure to join them at DDP 2015 in order to learn more. Register for Drug Delivery Partnerships now and use the code XP2078BLOG to save $300!